401 related articles for article (PubMed ID: 31915861)
1. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.
Appiah-Kusi E; Petros N; Wilson R; Colizzi M; Bossong MG; Valmaggia L; Mondelli V; McGuire P; Bhattacharyya S
Psychopharmacology (Berl); 2020 Apr; 237(4):1121-1130. PubMed ID: 31915861
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
Bergamaschi MM; Queiroz RH; Chagas MH; de Oliveira DC; De Martinis BS; Kapczinski F; Quevedo J; Roesler R; Schröder N; Nardi AE; Martín-Santos R; Hallak JE; Zuardi AW; Crippa JA
Neuropsychopharmacology; 2011 May; 36(6):1219-26. PubMed ID: 21307846
[TBL] [Abstract][Full Text] [Related]
3. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.
Bhattacharyya S; Wilson R; Appiah-Kusi E; O'Neill A; Brammer M; Perez J; Murray R; Allen P; Bossong MG; McGuire P
JAMA Psychiatry; 2018 Nov; 75(11):1107-1117. PubMed ID: 30167644
[TBL] [Abstract][Full Text] [Related]
4. Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report.
Davies C; Appiah-Kusi E; Wilson R; Blest-Hopley G; Bossong MG; Valmaggia L; Brammer M; Perez J; Allen P; Murray RM; McGuire P; Bhattacharyya S
Eur Arch Psychiatry Clin Neurosci; 2022 Apr; 272(3):461-475. PubMed ID: 34480630
[TBL] [Abstract][Full Text] [Related]
5. Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study.
Spinella TC; Stewart SH; Naugler J; Yakovenko I; Barrett SP
Psychopharmacology (Berl); 2021 Jul; 238(7):1965-1977. PubMed ID: 33813611
[TBL] [Abstract][Full Text] [Related]
6. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol.
Davies C; Bossong MG; Martins D; Wilson R; Appiah-Kusi E; Blest-Hopley G; Zelaya F; Allen P; Brammer M; Perez J; McGuire P; Bhattacharyya S
Psychol Med; 2024 Apr; 54(5):993-1003. PubMed ID: 37845827
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.
Linares IM; Zuardi AW; Pereira LC; Queiroz RH; Mechoulam R; Guimarães FS; Crippa JA
Braz J Psychiatry; 2019; 41(1):9-14. PubMed ID: 30328956
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial.
Dixon T; Cadenhead KS
Trials; 2023 Nov; 24(1):775. PubMed ID: 38037108
[TBL] [Abstract][Full Text] [Related]
9. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
O'Neill A; Wilson R; Blest-Hopley G; Annibale L; Colizzi M; Brammer M; Giampietro V; Bhattacharyya S
Psychol Med; 2021 Mar; 51(4):596-606. PubMed ID: 31994476
[TBL] [Abstract][Full Text] [Related]
10. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis.
Davies C; Wilson R; Appiah-Kusi E; Blest-Hopley G; Brammer M; Perez J; Murray RM; Allen P; Bossong MG; McGuire P; Bhattacharyya S
Transl Psychiatry; 2020 Sep; 10(1):311. PubMed ID: 32921794
[TBL] [Abstract][Full Text] [Related]
11. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
Hahn B
Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
[TBL] [Abstract][Full Text] [Related]
12. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease.
de Faria SM; de Morais Fabrício D; Tumas V; Castro PC; Ponti MA; Hallak JE; Zuardi AW; Crippa JAS; Chagas MHN
J Psychopharmacol; 2020 Feb; 34(2):189-196. PubMed ID: 31909680
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
García-Gutiérrez MS; Navarrete F; Gasparyan A; Austrich-Olivares A; Sala F; Manzanares J
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33228239
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial.
Gundugurti PR; Banda N; Yadlapalli SSR; Narala A; Thatikonda R; Kocherlakota C; Kothapalli KS
Asian J Psychiatr; 2024 Jul; 97():104073. PubMed ID: 38797087
[TBL] [Abstract][Full Text] [Related]
15. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder.
Bolsoni LM; Crippa JAS; Hallak JEC; Guimarães FS; Zuardi AW
Psychopharmacology (Berl); 2022 May; 239(5):1499-1507. PubMed ID: 35029706
[TBL] [Abstract][Full Text] [Related]
16. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
[TBL] [Abstract][Full Text] [Related]
17. Stressor-Cortisol Concordance Among Individuals at Clinical High-Risk for Psychosis: Novel Findings from the NAPLS Cohort.
Cullen AE; Addington J; Bearden CE; Stone WS; Seidman LJ; Cadenhead KS; Cannon TD; Cornblatt BA; Mathalon DH; McGlashan TH; Perkins DO; Tsuang MT; Woods SW; Walker EF
Psychoneuroendocrinology; 2020 May; 115():104649. PubMed ID: 32197198
[TBL] [Abstract][Full Text] [Related]
18. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats.
Resstel LB; Tavares RF; Lisboa SF; Joca SR; Corrêa FM; Guimarães FS
Br J Pharmacol; 2009 Jan; 156(1):181-8. PubMed ID: 19133999
[TBL] [Abstract][Full Text] [Related]
19. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
20. The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study.
Bloomfield MAP; Yamamori Y; Hindocha C; Jones APM; Yim JLL; Walker HR; Statton B; Wall MB; Lees RH; Howes OD; Curran VH; Roiser JP; Freeman TP
Psychopharmacology (Berl); 2022 May; 239(5):1539-1549. PubMed ID: 35445839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
